Although chemotherapy is generally recommended for triple negative breast cancers, the decision should be individualized for apocrine tumors that demonstrate low proliferation (low Ki-67) and favorable clinicopathologic features. The gene discussed is MKI67; the disease is triple-negative breast carcinoma.